Reuters logo
BRIEF-Glaxosmithkline receives FDA approval for new self-injectable formulation of Benlysta
July 21, 2017 / 1:05 PM / 5 months ago

BRIEF-Glaxosmithkline receives FDA approval for new self-injectable formulation of Benlysta

July 21 (Reuters) - Glaxosmithkline Plc:

* Receives FDA approval for a new self-injectable formulation of benlysta (belimumab) for systemic lupus erythematosus

* Benlysta subcutaneous formulation will be available in specialty pharmacies in us in late August

* Further regulatory submissions for subcutaneous formulation of benlysta under review, planned in other countries during course of 2017 Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below